At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 79 enrolled
Drug / intervention
Elestat +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Center, Masked, Randomized Study Comparing Two Marketed Ocular Anti-Allergy Medications in the Cat Room Model
In Brief
A Phase 4 clinical trial evaluating Elestat and Pataday for Allergic Conjunctivitis. Completed, enrolled 79 participants across 1 site.
Detailed Summary
The purpose of this study is to compare the effects of two marked ocular anti-allergy medications in cat sensitive subjects with allergic conjunctivitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Conjunctivitis
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 2007
Enrollment StartOct 2007
Primary CompletionJan 2008
TodayJul 2026
First PostedSep 26, 2007
Enrollment StartOct 1, 2007
Primary CompletionJan 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 18.8 years ago
Interventions
Elestatdrug
Elestat BID for 2 days
Patadaydrug
Pataday QD for 2 days